BD Collaborates with Fleming Fund to Help Combat Threat of Antimicrobial Resistance in Asia and sub-Saharan Africa
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a new, $6 million contract with the Fleming Fund, a U.K. aid program that helps low- and middle-income countries around the world tackle antimicrobial resistance (AMR).
Through this agreement, BD will provide diagnostic equipment and informatics solutions that help aid in the diagnosis of infections and guide physicians to provide appropriate antimicrobial prescribing and use.
Specifically, BD will equip more than 70 labs with solutions that include the BD BACTEC™ FX40 Blood Culture System designed for the rapid detection of bacteria and fungi in clinical specimens; blood and blood products; the BD Phoenix™ M50 Automated Microbiology System for the rapid identification (ID) and Antimicrobial Susceptibility Testing (AST) of clinically significant bacteria; and the BD™ Bruker MALDI Biotyper™ System for the rapid identification (ID) of microorganisms. For microbiology data management and informatics solutions, BD will be providing the BD EpiCenter™ Microbiology Data Management System and the BD Synapsys™ Microbiology Informatics Solution.
Boosting innovation in AMR?
15 OCT 2020: online Kick Off event AMR Innovation Mission UK 2021
The AMR Innovation Mission UK 2020/2021 aims to add to the global curbing of AMR by boosting joint early & translational research, R&D, clinical development, validation, registration and commercialisation of vaccines, microbial diagnostics and antimicrobial products.